Gynogen HP 75IU Injection contains Menotrophin, a highly purified preparation of follicle-stimulating hormone (FSH) and luteinizing hormone (LH) in a fixed ratio of 75 IU. It is indicated for use in the treatment of infertility in women caused by anovulation or oligo-ovulation, including cases associated with polycystic ovary syndrome (PCOS), hypogonadotropic hypogonadism, and other conditions where endogenous gonadotropin secretion is insufficient. Menotrophin acts by stimulating the growth and maturation of ovarian follicles, thereby promoting ovulation. The injection is administered intramuscularly or subcutaneously under medical supervision, with dosage and duration tailored to the patient’s response, as monitored by serum hormone levels and ultrasound assessment of follicular development. Gynogen HP 75IU Injection should be used with caution in patients with ovarian cysts, hypersensitivity to gonadotropins, or hormone-sensitive malignancies. Adverse effects may include ovarian hyperstimulation syndrome (OHSS), multiple pregnancies, injection site reactions, and headache. It is contraindicated in pregnancy, unexplained uterine bleeding, and primary ovarian failure. Proper patient selection and monitoring are essential to minimize risks and optimize therapeutic outcomes. This product should be stored as per manufacturer’s instructions and used only under the guidance of a qualified healthcare professional.